由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
_pennystock版 - 10/10扫描股票
相关主题
PPHM生拉AVNR
肝病生拉月末有event | ANDS| IDIXEvents and ER for week August 2-6 (转载)
【Biotech Event Thread】2009 OctEvents and ERs for week Aug 9-13 (转载)
[合集] Biotech Stocks Facing FDA Approval 四月至十月sppi
止痛药ACUR,CADXSOMX
收到一个号称我的BROKER的EMAIL,关于SPPI光头Biotech Calendar: Key Dates for September
JAZZ发新股了?ARNA failed to get approval
问一个JAV被收购的问题明天SPPI要摇铃开市了,是个利好吗?
相关话题的讨论汇总
话题: officers话题: progenics话题: difficile话题: paul话题: maddon
1 (共1页)
y*****l
发帖数: 5997
y*****l
发帖数: 5997
2
药股: Progenics Pharmaceuticals Inc PGNX:NASDAQ
Progenics Awarded $4.1 Million NIH Grant to Advance Novel C. Difficile
Antibody Therapy
Wednesday 10/06/2010 9:00 AM ET - Businesswire
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the award of
a grant totaling $4,143,652 from the National Institutes of Health (NIH) for
Progenics' program to develop novel monoclonal antibodies to treat
Clostridium difficile (C. difficile) infection. C. difficile is a bacterium
that represents the leading cause of hospital-acquired diarrhea in the
United States and a serious global public health challenge. Progenics'
monoclonal antibodies constitute a non-antibiotic treatment strategy that is
designed to block the harmful effects of the disease-causing toxins
produced by C. difficile.
"We are honored to receive this competitive NIH award and are gratified that
NIH elected to support our program based on its scientific merit,
innovation and therapeutic potential," said Paul J. Maddon, M.D., Ph.D.,
Founder, Chief Executive Officer and Chief Science Officer of Progenics
Pharmaceuticals, Inc. "The award acknowledges the growing burden of C.
difficile infection and the need for innovative therapies that go beyond
standard antibiotic approaches."
Insider Transaction History
Transaction Date Name/
Position Transaction Type Current Average
6 Month Return Market Value Shares Price Range Total
Holdings
October 4, 2010 Maddon, Paul J
Officers Purchase -0.31% $25K 5,000.00 $4.99 - 4.99
844,057.00
October 1, 2010 Mckinney, Robert A
Officers Exercise of Stock Options -- $35.5K 8,229.00 $4
.32 - 4.32 44,442.00
October 1, 2010 Israel, Robert J
Officers Exercise of Stock Options -- $37.9K 8,786.00 $4
.32 - 4.32 42,851.00
October 1, 2010 Baker, Mark Robert
Officers Exercise of Stock Options -- $75.8K 17,545.00 $
4.32 - 4.32 29,186.00
October 1, 2010 Olson, William C
Officers Exercise of Stock Options -- $29.9K 6,915.00 $4
.32 - 4.32 46,871.00
September 1, 2010 Maddon, Paul J
Officers Purchase -0.31% $20.5K 5,000.00 $4.10 - 4.10
839,057.00
August 2, 2010 Maddon, Paul J
Officers Purchase -0.31% $23.8K 5,000.00 $4.75 - 4.75
834,057.00
July 16, 2010 Maddon, Paul J
Officers Purchase -0.31% $24.9K 5,000.00 $4.98 - 4.99
829,057.00
1 (共1页)
相关主题
明天SPPI要摇铃开市了,是个利好吗?止痛药ACUR,CADX
没人看见吗...ARNA终于还是悲剧了,看周一反应吧收到一个号称我的BROKER的EMAIL,关于SPPI
推荐sppiJAZZ发新股了?
RPC问一个JAV被收购的问题
PPHM生拉AVNR
肝病生拉月末有event | ANDS| IDIXEvents and ER for week August 2-6 (转载)
【Biotech Event Thread】2009 OctEvents and ERs for week Aug 9-13 (转载)
[合集] Biotech Stocks Facing FDA Approval 四月至十月sppi
相关话题的讨论汇总
话题: officers话题: progenics话题: difficile话题: paul话题: maddon